New Tool: ProSource
Checkout our packaging and processing solutions finder, ProSource.
Start Your Search

Experimental Alopecia Pill Shows Promise

If results of a new Phase 3 study are successful, Concert Pharmaceuticals will likely submit the drug for FDA approval next year.

Concert Pharmaceutical
Concert Pharmaceuticals

If this year’s Oscars did anything, it put the severe form of hair loss known as alopecia in the limelight. The disease causes the body’s immune system to attack hair follicles, resulting in patchy hair loss, or in some cases total hair loss. Currently, there are no approved treatments for the disease. But according to a recent Boston Globe article, those afflicted with the condition have new hope in the form of a pill. An experimental treatment from Concert Pharmaceuticals has restored a near full head of hair in roughly 30-40% of people with alopecia.

The drug, known as CTP-543, was tested on a group of roughly 700 people with varying degrees of hair loss due to alopecia. The 6-month study examined how many people were able to regrow hair to cover at least 80% of their scalp. Concert met their goal for 29.6% of people who received a medium dose of the drug, and 41.5% of people who received a high dose of the drug. The team is optimistic that the numbers will increase as time goes on as some peoples hair will take longer to respond. 

Test Your Supply Chain Smarts
Take Healthcare Packaging's supply chain quiz to prove your knowledge!
Take Quiz
Test Your Supply Chain Smarts
Discover Our Content Hub
Access Healthcare Packaging's free educational content library!
Unlock Learning Here
Discover Our Content Hub